<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zannad, Faiez</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">NECTAR-HF: Cardiac Remodeling Not Reduced with VNS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Vagal nerve stimulation (VNS) did not reduce the primary end point of cardiac remodeling at 6 months in patients who had heart failure (HF) with reduced ejection fraction in the first sham-controlled, double-blind clinical trial to evaluate this approach. The Neutral Cardiac Therapy for Heart Failure study [NECTAR-HF; Zannad F et al. Eur Heart J. 2014] sought to determine whether an implanted VNS system would reset the altered autonomic nervous system balance found in HF. The 6-month data were presented, and follow-up will continue to 18 months.</style></abstract><number><style face="normal" font="default" size="100%">27</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>